In the SURMOUNT trials evaluating tirzepatide for weight management, diarrhea occurred in 19-24% of participants across doses, making it one of the most common gastrointestinal complaints alongside nausea and vomiting
The system may require patient identity verification, provider information confirmation, and electronic consent and signatures
Understanding why these FDA-approved GLP-1 receptor agonists may not work as expected requires examining multiple factorsfrom medication dosing and administration technique to underlying medical conditions and lifestyle behaviors
Traditional Medicare does not currently cover semaglutide for weight management purposes
Stepping down from 2.4 mg to 1.7 mg or even 1.0 mg after achieving goal weight can reduce side effects and medication cost while maintaining some appetite suppression
While temporary fatigue may occur early in treatment, improved blood sugar stability, weight loss, and better metabolic function often lead to increased energy over time